港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

泰德医药

40.220

+1.3203.39%

成交量：6.17万

成交额：241.77万

市值：57.11亿

市盈率：84.96

高：40.400

开：38.000

低：38.000

收：38.900

52周最高：41.720

52周最低：28.100

股本：1.42亿

香港流通股本：7,359.89万

量比：0.41

换手率：0.08%

股息：- -

股息率：- -

每股收益(LYR):0.473

净资产收益率：20.67%

总资产收益率：5.25%

市净率：16.42

市盈率(LYR):84.96

市销率: 11.83

数据加载中...

总览公司新闻公告

异动解读 | 泰德医药上市首日盘中大涨5.23%，全球第三大多肽CRDMO前景看好

异动解读 | 泰德医药首日挂牌大涨5.23%，全球第三大多肽CRDMO受市场追捧

一家CRDMO港股上市，CRO项目1217个

生物药大时代

异动解读 | 泰德医药首日挂牌大跌5.07%，IPO超购301倍后遇冷

新股定价｜泰德医药公开发售超购300倍，一手中签50%

老虎资讯综合

新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元

老虎暗盘｜泰德医药盘初拉升，为“全球第三大多肽CRDMO”

老虎资讯综合

多肽CRDMO新贵赴港IPO

多肽药物“卖水人”，泰德医药(03880.HK)港股上市能否借势起飞？

46个人11亿营收，if椰子水要IPO了

【新股IPO】中泰国际予泰德医药IPO评分70分予“申购”评级

泰德医药港股IPO，站在减肥药的风口上卖原料

医疗健康领域投融资日报（6月20日）：浙江泰德医药完成1000万美元Pre-IPO融资

泰德医药：创新药牛市+减肥药卖铲人概念，能打吗？

财经自媒体

新股招股｜泰德医药今起招股，一手入场费约3090.85港元

老虎资讯综合

泰德医药(03880)6月20日至6月25日招股预计6月30日上市

【新股IPO】泰德医药(浙江)股份有限公司通过港交所主板上市聆讯

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/03880/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03880","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03880\",,,,,undefined,":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"泰德医药","latestPrice":40.22,"timestamp":1756179043784,"preClose":38.9,"halted":0,"volume":61700,"delay":0,"floatShares":73598888,"shares":142000000,"eps":0.473384,"marketStatus":"交易中","change":1.32,"latestTime":"08-26 11:35:21","open":38,"high":40.4,"low":38,"amount":2417706,"amplitude":0.061697,"askPrice":40.3,"askSize":1100,"bidPrice":40.22,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.376814,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1756180800000},"marketStatusCode":2,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":38.9,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.411939,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03880\",,,,,undefined,":{"symbol":"03880","floatShares":73598888,"roa":"5.25%","roe":"20.67%","lyrEps":0.473384,"volumeRatio":0.411939,"shares":142000000,"dividePrice":0,"high":40.4,"amplitude":0.061697,"preClose":38.9,"low":38,"week52Low":28.1,"pbRate":"16.42","psRate":"11.83","week52High":41.72,"institutionHeld":0,"latestPrice":40.22,"committee":-0.047619,"eps":0.473384,"divideRate":0,"volume":61700,"delay":0,"ttmEps":0.376814,"open":38,"prevYearClose":30.6,"prevWeekClose":40.64,"prevMonthClose":35.7,"prevQuarterClose":30.8,"fiveDayClose":37.32,"twentyDayClose":34.15,"sixtyDayClose":30.6,"earningDate":1756396800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03880\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"03880","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03880\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03880\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/03880\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"03880","date":"2025-08-25","current":85.333848,"percent":0.95,"low":64.550519,"twenty":69.032987,"median":74.113313,"eighty":78.454706,"high":89.502411,"avg":74.870586,"sd":5.452349,"marketCap":5516020000},"quantilePoints":[{"date":"2025-06-27","current":64.550519,"twenty":64.550519,"median":64.550519,"eighty":64.550519,"marketCap":4183100000},{"date":"2025-07-04","current":69.032987,"twenty":66.795355,"median":68.595377,"eighty":69.313609,"marketCap":4473790000},{"date":"2025-07-11","current":68.445519,"twenty":67.311524,"median":68.276633,"eighty":68.994281,"marketCap":4431250000},{"date":"2025-07-18","current":76.171108,"twenty":67.389311,"median":68.984604,"eighty":75.214843,"marketCap":4927550000},{"date":"2025-07-25","current":74.03868,"twenty":67.965697,"median":71.906475,"eighty":74.616858,"marketCap":4807020000},{"date":"2025-08-01","current":77.026259,"twenty":68.377965,"median":73.828208,"eighty":76.342138,"marketCap":4970090000},{"date":"2025-08-08","current":73.611635,"twenty":68.565405,"median":73.719922,"eighty":75.214843,"marketCap":4761644000},{"date":"2025-08-15","current":78.991101,"twenty":68.906759,"median":73.83709,"eighty":76.342138,"marketCap":5101964000},{"date":"2025-08-22","current":89.502411,"twenty":69.02331,"median":74.090002,"eighty":78.320217,"marketCap":5762752000},{"date":"2025-08-25","current":85.333848,"twenty":69.032987,"median":74.113313,"eighty":78.454706,"marketCap":5516020000}],"updateTime":1756179321111},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03880\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151587210","title":"异动解读 | 泰德医药上市首日盘中大涨5.23%，全球第三大多肽CRDMO前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1151587210","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151587210?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 13:06","pubTimestamp":1751260007,"startTime":"0","endTime":"0","summary":"6月30日，全球第三大专注于多肽的CRDMO服务商泰德医药在港交所挂牌上市。截至发稿，该股盘中大涨5.23%，引发市场关注。泰德医药此次IPO获得投资者热烈追捧，公开发售部分获301.15倍超额认购。上市首日开盘价为30.3港元，略低于发行价，但随后股价迅速拉升。分析人士认为，泰德医药股价上涨主要有以下几个原因：首先，公司是全球第三大专注于多肽的CRDMO，市场份额达1.5%，在行业中具有领先地位。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ec850e8897536c756ef52d3b59f79c38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"1170125532","title":"异动解读 | 泰德医药首日挂牌大涨5.23%，全球第三大多肽CRDMO受市场追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1170125532","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170125532?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 13:06","pubTimestamp":1751259991,"startTime":"0","endTime":"0","summary":"6月30日，泰德医药在港交所正式挂牌上市，盘中股价大涨5.23%。截至下午1点04分，泰德医药报32.2港元，总市值达45.7亿港元。分析人士认为，泰德医药股价的强势表现反映了投资者对公司在快速增长的多肽CRDMO市场中的领先地位的认可，以及对其未来在GLP-1等热门领域发展潜力的看好。随着全球多肽药物市场的持续扩张，泰德医药有望受益于行业增长红利，进一步巩固其市场地位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ec850e8897536c756ef52d3b59f79c38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"2547566060","title":"一家CRDMO港股上市，CRO项目1217个","url":"https://stock-news.laohu8.com/highlight/detail?id=2547566060","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547566060?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 12:32","pubTimestamp":1751257920,"startTime":"0","endTime":"0","summary":"泰德医药发售价为每股H股30.60港元，市值43.49亿港元。全球多肽CRDMO市场约有150名多肽CRDMO服务供应商。其专注于多肽的合约研究、开发及生产机构，是全球第三大多肽CRDMO。截至2024年12月31日，泰德医药拥有1217个在研CRO项目、332个在研CDMO项目。2024年，CDMO服务贡献3.3亿元收入，占比74.6%，美国市场营收占比55%，远超内地市场的21.4%。目前，泰德医药正推进与7位客户的9个NCE GLP-1项目开发，涵盖临床前至临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630130025a7253d32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630130025a7253d32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","03880","HSCEI"],"gpt_icon":1},{"id":"1133551242","title":"异动解读 | 泰德医药首日挂牌大跌5.07%，IPO超购301倍后遇冷","url":"https://stock-news.laohu8.com/highlight/detail?id=1133551242","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133551242?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 09:36","pubTimestamp":1751247406,"startTime":"0","endTime":"0","summary":"6月30日，全球第三大专注于多肽的CRDMO泰德医药在港交所主板挂牌上市，但开市后股价表现不佳。截至上午9:34，泰德医药股价大跌5.07%，显示出投资者对该新股的谨慎态度。泰德医药此次IPO发行价为每股30.60港元，共发行1680万股股份。然而，上市首日股价的下跌反映出市场情绪的快速转变。泰德医药计划将此次IPO募集的资金用于扩大在美国和中国的产能，发展寡核苷酸业务，以及在欧洲设立销售及售后服务办事处。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2df76ee7ea8420c4a03b3e945881ac96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 泰德医药首日挂牌大跌5.07%，IPO超购301倍后遇冷","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"1107008937","title":"新股定价｜泰德医药公开发售超购300倍，一手中签50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107008937","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107008937?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 07:54","pubTimestamp":1751241271,"startTime":"0","endTime":"0","summary":"6月30日，  $泰德医药$公布配发结果，每股定价30.60港元，共发行1680万股股份，每手100股，今日正式上市。上一交易日，泰德医药暗盘低开，收涨1.8%，报31.15港元，成交额8263.13万港元，总市值44.17亿港元。公开发售阶段泰德医药获301.15倍认购，经重新分配后，公开发售的发售股份最终数目为840万股股份，占发售股份总数的约50%。泰德医药主要提供CRO服务，即多肽NCE发现合成；及CDMO服务，即多肽CMC开发以及商业化生产。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股定价｜泰德医药公开发售超购300倍，一手中签50%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":1},{"id":"2546974197","title":"新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546974197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546974197?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:21","pubTimestamp":1751012476,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，泰德医药(03880)将于6月30日(星期一)在香港挂牌。截至发稿，暗盘交易显示报价31.25港元，较招股价30.6港元上涨2.12%，每手100股，不计手续费，每手赚65港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1310798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880"],"gpt_icon":0},{"id":"1169056197","title":"老虎暗盘｜泰德医药盘初拉升，为“全球第三大多肽CRDMO”","url":"https://stock-news.laohu8.com/highlight/detail?id=1169056197","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169056197?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:17","pubTimestamp":1751012226,"startTime":"0","endTime":"0","summary":"有望受益于“减肥神药”行情。","market":"hk","thumbnail":"https://static.tigerbbs.com/94a20e74d3a441172ddc7ee6bc0c81f2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/94a20e74d3a441172ddc7ee6bc0c81f2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":0},{"id":"2546760566","title":"多肽CRDMO新贵赴港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2546760566","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546760566?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 11:56","pubTimestamp":1750996582,"startTime":"0","endTime":"0","summary":"6月的港股创新药市场再掀波澜——继核药龙头先通医药递交上市申请后，专注于多肽领域的CRDMO企业泰德医药于6月20日正式开启招股，预计6月30日登陆港交所主板。这家全球第三大多肽CRDMO企业的IPO进程，不仅标志着中国医药外包产业在细分领域的突破，更折射出多肽药物黄金赛道的资本热度。千亿赛道的黄金驱动力泰德医药所处的多肽CRDMO赛道，正迎来前所未有的发展机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627120048a4c040d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627120048a4c040d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":1},{"id":"2546592293","title":"多肽药物“卖水人”，泰德医药(03880.HK)港股上市能否借势起飞？","url":"https://stock-news.laohu8.com/highlight/detail?id=2546592293","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546592293?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 14:36","pubTimestamp":1750833380,"startTime":"0","endTime":"0","summary":"凭借前期深厚技术沉淀、完善业务布局以及优质客户资源积累，泰德医药已站上行业前沿，能够充分承接市场增长带来的红利。","market":"us","thumbnail":"https://img7.gelonghui.com/column/4.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/4.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2385057","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["03880","YANG","HSTECH","BK4614"],"gpt_icon":1},{"id":"2545875442","title":"46个人11亿营收，if椰子水要IPO了","url":"https://stock-news.laohu8.com/highlight/detail?id=2545875442","media":"投资家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545875442?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 20:21","pubTimestamp":1750767660,"startTime":"0","endTime":"0","summary":"此次调整标志着美团收缩社区团购战线，转向即时零售与海外市场的战略重心转移。核心产品Tinengotinib为全球首创MTK抑制剂，针对胆管癌等适应症进入III期临床，海外权益授权金额超5亿美元。IFBH是一家植根泰国的即饮饮料及即食食品公司，旗下if品牌椰子水在内地和香港市场占有率颇高。此外，环保杯0.1美元折扣仍保留。“6·18”期间玩具潮玩领域6家商家销售额破亿，盲盒爆款秒空，骑行、宠物等情","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/fundzmt/2025-06-24/doc-infcerum5477999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03880","09678","06603"],"gpt_icon":0},{"id":"2545474803","title":"【新股IPO】中泰国际予泰德医药IPO评分70分 予“申购”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2545474803","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545474803?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 13:31","pubTimestamp":1750743072,"startTime":"0","endTime":"0","summary":"2024年收入同比增加31.3%，股东净利润同比增加21.0%，资产负债表健康。由于医药研发与生产外包行业的业务中，多肽药物的增速明显快于该行业的总体水平，因此该机构认为专注于多肽药物的企业应存在估值溢价，港股企业可比性不强，因此该机构也参考A股。公司招股价对应的估值较A股同业有折让，因此该机构认为估值仍合理，而且公司保荐人往绩记录良好，新股市场畅旺，给予“申购”评级及70分的评分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062413314095290c0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062413314095290c0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":1},{"id":"2545129174","title":"泰德医药港股IPO，站在减肥药的风口上卖原料","url":"https://stock-news.laohu8.com/highlight/detail?id=2545129174","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545129174?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 20:16","pubTimestamp":1750680960,"startTime":"0","endTime":"0","summary":"泰德医药的战略重心是GLP-1类药物，这类药物因减肥和糖尿病治疗效果显著被称为“神药”，全球市场规模预计从2023年的389亿美元增长至2032年的1299亿美元。泰德医药按调整后净利润计算，估值22倍，这个估值不贵，而且公司作为港股唯一纯多肽CRDMO企业，且绑定GLP-1风口，估值存在技术溢价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-23/doc-infcanuy0369413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HSTECH","YANG","BK4614","03880"],"gpt_icon":1},{"id":"2545484420","title":"医疗健康领域投融资日报（6月20日）：浙江泰德医药完成1000万美元Pre-IPO融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2545484420","media":"亿欧网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545484420?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 07:00","pubTimestamp":1750460400,"startTime":"0","endTime":"0","summary":"联影智能总部位于中国上海市，是一家高端医疗影像设备研发生产商；3.北检检测完成1000万人民币A轮融资，该公司总部位于中国山东省，是一家生物安全与动物实验室。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622025141a716579f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250622025141a716579f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2544120563","title":"泰德医药：创新药牛市+减肥药卖铲人概念，能打吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2544120563","media":"财经自媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544120563?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 19:53","pubTimestamp":1750420380,"startTime":"0","endTime":"0","summary":"今日，港交所一口气批了3只新股，分别是IFBH、云知声和泰德医药。简而言之，泰德医药是帮助创新药公司做临床实验及代工生产药物的，与药明康德、凯莱英等公司是竞争对手。信邦制药因此计提商誉减值15.37亿元，归母净亏损12.97亿元，为上市以来首次亏损。由此来看，泰德医药算不上好公司，无非是赶上多肽药的爆发。不过，从今日药捷安康暗盘大涨68.8%、佰泽医疗涨超25%来看，医药股仍然受到投资者追捧，泰德医药或将延续创新药新股神话！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-06-20/doc-infatrke3836523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","03880","06978"],"gpt_icon":1},{"id":"1173753255","title":"新股招股｜泰德医药今起招股，一手入场费约3090.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173753255","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173753255?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 08:46","pubTimestamp":1750380364,"startTime":"0","endTime":"0","summary":"6月20日，$泰德医药$于2025年6月20日至6月25日招股，公司拟发售1680万股，香港发售占10%，国际发售占90%。每股发售价28.4-30.6港元，每手100股，预期股份将于6月30日开始在联交所买卖。申购阶梯：每手100股，入场费3090.85港元。乙组门槛为20万股，申购所需资金约618.17万港元。公司为客户提供符合全球主要市场监管规定的多肽类药物开发、生产、 CMC申报支持服务。所得款项净额的约4.1%将用于扩张中国的产能。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜泰德医药今起招股，一手入场费约3090.85港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":0},{"id":"2544948871","title":"泰德医药(03880)6月20日至6月25日招股 预计6月30日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2544948871","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544948871?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 07:04","pubTimestamp":1750374293,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 于2025年6月20日至6月25日招股，公司拟发售1680万股，香港发售占10%，国际发售占90%。每股发售价28.4-30.6港元，每手100股，预期股份将于2025年6月30日(星期一)开始在联交所买卖。公司已在超过50个国家建立稳定的客户关系和服务范围，其中包括中国、美国、日本、欧洲、韩国及澳大利亚等主要市场。公司为客户提供符合全球主要市场监管规定的多肽类药物开发、生产、 CMC申报支持服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1307511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1161","03880","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"2540706817","title":"【新股IPO】泰德医药(浙江)股份有限公司通过港交所主板上市聆讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2540706817","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540706817?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 00:44","pubTimestamp":1748969040,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所6月3日披露，泰德医药 股份有限公司通过港交所主板上市聆讯，摩根士丹利和中信证券为联席保荐人。根据弗若斯特沙利文的资料，于2023年，按销售收入计，公司是全球第三大专注于多肽的CRDMO，市场份额为1.5%。公司提供从早期发现、临床前研究及临床开发以至商业化生产的全周期服务。以多肽为核心的全球CRDMO市场的两大参与者占23.8%的市场份额，其余市场参与者则较为分散，2023年第三至六大参与者分别仅占约1%的市场份额。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTdjODg5ZDM1NDI1NjgyNDQyMw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1959802","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1515","09939","03880","BK1574","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}]}}